Estrostep

Ethinylestradiol/norethisterone acetate

Ethinylestradiol/norethisterone acetate

Pharmaceutical combination

Not to be confused with Ethinylestradiol/norethisterone.

Ethinylestradiol/norethisterone acetate (EE/NETA), or ethinylestradiol/norethindrone acetate, is a combination of ethinylestradiol (EE) and norethisterone acetate (NETA) which is used as birth control and menopausal hormone therapy.[1][2] EE is an estrogen, while norethisterone acetate (NETA) is a progestin.[1] It is taken by mouth.[1] Some preparations of EE/NETA used in birth control additionally contain an iron supplement in the form of ferrous fumarate.[3]

Quick Facts Combination of, Norethisterone acetate ...

In 2021, it was the 52nd most commonly prescribed medication in the United States, with more than 12 million prescriptions.[4][5] It is available as a generic medication.[6]

In addition, branded formulations of this hormone combination when used for birth control are only available by prescription in the US.

Society and culture

Brand names

Brand names include Anovlar, Blisovi, Cumorit, Estrostep, FemHRT, Fyavolv, Gildess, Junel,[7] Larin, Leribane, Loestrin, Lo Loestrin (Lo Lo), Mibelas, Microgestin, Minastrin, Norlestrin, Primodos, Taytulla, and Tri-Legest, among others.[6][8]

In addition, the combination is sold in the United States under the brand name Femhrt for use in menopausal hormone therapy.[9][10][2]

See also

References

  1. [1]
    "Estrogen-Progestin Combinations Monograph for Professionals". Drugs.com. AHFS. Retrieved 28 December 2018.
  2. [2]
    Rowan JP, Simon JA, Speroff L, Ellman H (June 2006). "Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials". Clin Ther. 28 (6): 921–32. doi:10.1016/j.clinthera.2006.06.013. PMID 16860174.
  3. [3]
    Willihnganz M, Clayton AD (1 May 2014). Basic Pharmacology for Nurses - E-Book. Elsevier Health Sciences. pp. 648–. ISBN 978-0-323-29309-9.
  4. [4]
    "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  5. [5]
    "Ethinyl Estradiol; Norethindrone - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
  6. [6]
    "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
  7. [7]
    "Junel 21 Day- norethindrone acetate and ethinyl estradiol tablet; Junel Fe 28 Day- norethindrone acetate and ethinyl estradiol and ferrous fumarate kit". DailyMed. 14 August 2023. Retrieved 27 February 2024.
  8. [8]
    "Ethinyl Estradiol and Norethindrone (Professional Patient Advice)". Drugs.com. 13 July 2019. Retrieved 10 April 2020.
  9. [9]
    "Drug Approval Package: Femhrt (Norethindrone Acetate & Ethinyl Estradiol) NDA #21065". U.S. Food and Drug Administration (FDA). Retrieved 28 December 2018.
  10. [10]
    "FemHRT- norethindrone acetate/ethinyl estradiol tablet". DailyMed. 14 November 2017. Retrieved 31 December 2019.
Share this article:

This article uses material from the Wikipedia article Estrostep, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.